Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: January 01, 2026 Report Code: GDHC335PIDR-8M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Understand the Crohn’s Disease therapeutics market across the 8 major markets with forecasts to 2032. Explore pipeline therapies, competitive benchmarking, treatment trends, unmet needs, clinical trial mapping, and strategic opportunities using GlobalData’s expert market analysis and Excel-based forecast model.

Crohn’s Disease Drug Market Forecast and Competitive Intelligence Across the 8MM

GlobalData’s Crohn’s Disease market report provides detailed analysis of the therapeutics landscape across the eight major markets (8MM), combining market forecasts, pipeline intelligence, competitive assessment, and treatment usage insights through 2032.

The report highlights that Crohn’s Disease drug sales across the 8MM are expected to increase from $9.5 billion to $13.8 billion by 2032, reflecting a CAGR of 3.9%. Growth is supported by the approval and launch of eight pipeline, generic, and biosimilar therapies.

In addition, the report delivers insight into epidemiology, diagnosis patterns, disease management approaches, unmet needs, clinical trial activity, and evolving treatment strategies. It also provides analysis of emerging mechanisms of action and late-stage pipeline candidates shaping the future of the Crohn’s Disease therapeutics market.

Built using GlobalData’s proprietary healthcare intelligence and forecasting methodologies, this report helps you evaluate market dynamics, benchmark competitors, and identify commercial opportunities across the global Crohn’s Disease landscape.

Report Value Proposition – Why This Matters for You

This report helps you understand where growth opportunities may emerge in the Crohn’s Disease therapeutics market through 2032.

You can use the report to assess pipeline competition, evaluate late-stage therapies, identify market access opportunities, and benchmark treatment trends across the 8MM. In addition, the Excel-based forecast model supports strategic planning, forecasting, licensing evaluations, and competitive positioning.

The report may help pharmaceutical companies, biotech firms, investors, and healthcare strategy teams strengthen commercialization strategies and evaluate future market risks and opportunities.

Moreover, the analysis combines quantitative forecasts with qualitative insight, helping you understand not only market size projections, but also the competitive and clinical factors influencing future demand.

Key Insights in the Crohn’s Disease Therapeutics Market

Crohn’s Disease therapeutics sales across the 8MM are forecast to rise from $9.5 billion to $13.8 billion by 2032.
The market is projected to grow at a CAGR of 3.9% during the forecast period.
Growth is supported by pipeline therapies, generics, and biosimilars entering the market.
The report includes epidemiology, diagnosis, symptoms, and disease management analysis.
Strategic competitor assessment and market characterization are covered in detail.
Clinical trial mapping and unmet needs analysis provide insight into future innovation areas.
Late-stage pipeline candidates and emerging mechanisms of action are profiled.
Competitive dynamics, market drivers, restraints, and challenges are independently analyzed.

Scope

What You Will Learn

Crohn’s Disease therapeutics market size and forecast across the 8MM

Treatment usage patterns and annualized therapy revenue forecasts through 2032

Key pipeline products and emerging therapeutic mechanisms

Market opportunities linked to generics, biosimilars, and late-stage assets

Competitive positioning of leading and emerging companies

Clinical trial activity and unmet treatment needs

Factors shaping current and future competition within the Crohn’s Disease market

Strategic implications of industry drivers, restraints, and market challenges

Target Buyers for This Report

This report may support strategic decision-making for:

Pharmaceutical companies developing gastrointestinal therapies

Biotechnology companies focused on inflammatory bowel disease (IBD)

Licensing and business development teams evaluating pipeline assets

Commercial strategy and market access teams

Healthcare consulting and advisory firms

Institutional and private equity investors evaluating healthcare opportunities

Competitive intelligence and forecasting teams

Clinical development and R&D strategy teams

How Companies Use This Report

Pharmaceutical and biotechnology companies may use this report to benchmark pipeline strategies, evaluate competitive positioning, and identify future commercialization opportunities.

For example:

Companies developing Crohn’s Disease biologics may use the report to assess competitor pipelines and treatment adoption trends.

Biosimilar manufacturers may use the forecast model to evaluate future market entry opportunities.

Healthcare investors and private equity firms may use the analysis to identify high-growth therapeutic segments and emerging players.

Commercial strategy teams may use treatment usage forecasts and competitive assessments to support launch planning and market prioritization.

In addition, organizations can use the report to benchmark against global leaders and better understand the competitive landscape across the 8MM.

Reasons to Buy

Benchmark Against Global Leaders and Emerging Innovators

The report provides insight into current and future market competition, helping you benchmark pipeline strength, commercialization strategies, and therapeutic positioning against leading and emerging market participants.

Moreover, the analysis of clinical trial mapping, mechanisms of action, and market characterization may help support strategic differentiation in an increasingly competitive Crohn’s Disease therapeutics market.

Built on Trusted GlobalData Healthcare Intelligence

Built on GlobalData’s proprietary healthcare databases and forecasting methodologies, this report combines epidemiology analysis, pipeline intelligence, clinical trial tracking, and market forecasting into a single strategic resource.

The analysis is supported by GlobalData’s healthcare sector expertise and may help organizations improve strategic planning, investment evaluation, licensing assessments, and competitive benchmarking.

Trusted by leading healthcare companies, investors, and strategy teams worldwide, GlobalData’s research provides actionable insight into evolving therapeutic markets.

Act Now to Capture Emerging Crohn’s Disease Market Opportunities

As pipeline therapies, biosimilars, and competitive dynamics continue to reshape the Crohn’s Disease therapeutics market, organizations need reliable market intelligence to support faster and more informed decisions.

This report provides the insight, forecasts, and competitive analysis needed to evaluate market trends, benchmark competitors, and identify growth opportunities through 2032.

AbbVie
Takeda
Janssen
Lilly
Merck
Sanofi
Pfizer
Abivax
Teva Pharmaceuticals
Roche
UCB

List of Contents

List of Tables

List of Figures

1 Crohn’s Disease: Executive Summary

1.1 Summary of changes

1.2 Steady growth is expected for the CD market from 2022–32

1.3 Novel MOAs will provide market shifts throughout the forecast period

1.4 Lack of tools to properly treat patients with CD is a clear unmet need within the market

1.5 Pipeline Drugs

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 CD Classification

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 8MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity

4.5 Epidemiological forecast for Crohn’s disease (2022–32)

4.5.1 Diagnosed incident cases of CD

4.5.2 Age-specific diagnosed incident cases of CD

4.5.3 Sex-specific diagnosed incident cases of CD

4.5.4 Diagnosed prevalent cases of CD

4.5.5 Age-specific diagnosed prevalent cases of CD

4.5.6 Sex-specific diagnosed prevalent cases of CD

4.5.7 Diagnosed prevalent cases of CD by severity

4.5.8 Diagnosed prevalent cases of fistulizing CD by severity

4.5.9 Diagnosed prevalent cases of CD in remission by severity

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission

7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis

7.4 Improved Medical Management of Perianal Fistulas

7.5 Clinical Data to Determine the Most Efficacious Therapy

8 R&D Strategies

8.1 Overview

8.1.1 Novel MOAs

8.1.2 Biomarkers

8.2 Clinical Trials Design

8.2.1 Patient inclusion criteria

8.2.2 Endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and barriers

12.5 Canada

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Global Director of Therapy Analysis and Epidemiology

About GlobalData

Table

Table 1: CD: Key metrics in the 8MM

Table 2: Summary of changes to CD Eight-Market Drug Forecast and Analysis to 2032

Table 3: Crohn’s disease severities

Table 4: Risk factors and comorbidities for CD

Table 5: Treatment guidelines for CD

Table 6: Top 10 deals by value, 2018–2024

Table 7: CD market – global drivers and barriers, 2022–32

Table 8: Key events impacting sales for CD in the US, 2022–32

Table 9: CD market – drivers and barriers in the US, 2022–32

Table 10: Key events impacting sales for CD in the 5EU, 2022–32

Table 11: CD market – drivers and barriers in the 5EU, 2022–32

Table 12: Key events impacting sales for CD in Japan, 2022–32

Table 13: CD market – drivers and barriers in Japan, 2022–32

Table 14: Key events impacting sales for CD in Canada, 2022–32

Table 15: CD market – drivers and barriers in Canada, 2022–32

Table 16: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for CD in 2022 and 2032

Figure 2: Analysis of the company portfolio gap in CD during the forecast period

Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira

Figure 4: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq

Figure 5: Pathophysiology of Crohn’s disease

Figure 6: 8MM, diagnosed incidence of CD, men and women, cases per 100,000 population, all ages, 2022

Figure 7: 8MM, diagnosed prevalence of CD, men and women, %, all ages, 2022

Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of CD

Figure 9: 8MM, sources used and not used to forecast the diagnosed prevalent cases of CD

Figure 10: 8MM, diagnosed incident cases of CD, N, both sexes, all ages, 2022

Figure 11: 8MM, diagnosed incident cases of CD by age, N, both sexes, 2022

Figure 12: 8MM, diagnosed incident cases of CD by sex, N, all ages, 2022

Figure 13: 8MM, diagnosed prevalent cases of CD, N, both sexes, all ages, 2022

Figure 14: 8MM, diagnosed prevalent cases of CD by age, N, both sexes, 2022

Figure 15: 8MM, diagnosed prevalent cases of CD by sex, N, all ages, 2022

Figure 16: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages <18 years, 2022

Figure 17: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages ≥18 years, 2022

Figure 18: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages <18 years, 2022

Figure 19: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages ≥18 years, 2022

Figure 20: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages <18 years, 2022

Figure 21: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages ≥18 years, 2022

Figure 22: Unmet needs and opportunities in CD

Figure 23: Overview of the development pipeline in CD

Figure 24: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for CD in the 8MM during the forecast period

Figure 25: Competitive assessment of the late-stage biologics benchmarked against Humira

Figure 26: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq

Figure 27: Analysis of the company portfolio gap in CD during the forecast period

Figure 28: Global (8MM) sales forecast by country for CD in 2022 and 2032

Figure 29: Sales forecast by class for CD in the US in 2022 and 2032

Figure 30: Sales forecast by class for CD in the 5EU in 2022 and 2032

Figure 31: Sales forecast by class for CD in Japan in 2022 and 2032

Figure 32: Sales forecast by class for CD in Canada in 2022 and 2032

Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Crohn's Disease (Regional Enteritis) reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 in real time.

Access a live Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

Crohn’s Disease Drug Market Forecast and Competitive Intelligence Across the 8MM

Report Value Proposition – Why This Matters for You

Key Insights in the Crohn’s Disease Therapeutics Market

Scope

What You Will Learn

Target Buyers for This Report

How Companies Use This Report

Reasons to Buy

Benchmark Against Global Leaders and Emerging Innovators

Built on Trusted GlobalData Healthcare Intelligence

Act Now to Capture Emerging Crohn’s Disease Market Opportunities

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports